Comparative Pharmacology
Head-to-head clinical analysis: CYTARABINE versus VERCYTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYTARABINE versus VERCYTE.
CYTARABINE vs VERCYTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cytarabine is a pyrimidine nucleoside analog that inhibits DNA synthesis. It is converted intracellularly to its active triphosphate form, which competes with deoxycytidine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase. It also inhibits DNA repair and RNA synthesis.
VERCYTE (luspatercept) is a recombinant fusion protein that acts as a ligand trap for members of the transforming growth factor-beta (TGF-β) superfamily, including GDF11. It binds to these ligands, inhibiting Smad2/3 signaling, thereby promoting late-stage erythroid differentiation and maturation.
100-200 mg/m² IV continuous infusion over 24 hours for 7 days (induction) or 1-3 g/m² IV every 12 hours for 3-6 days (high-dose). Intrathecal: 30-100 mg/m² (max 100 mg) once every 2-7 days.
150 mg orally once daily for 5 consecutive days, then 150 mg orally once daily every other day (on days 1, 3, 5) for a total cycle of 28 days. Administer on an empty stomach (1 hour before or 2 hours after meals).
None Documented
None Documented
Clinical Note
moderateCytarabine + Digoxin
"Cytarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCytarabine + Digitoxin
"Cytarabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCytarabine + Deslanoside
"Cytarabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCytarabine + Acetyldigitoxin
"Cytarabine may decrease the cardiotoxic activities of Acetyldigitoxin."
Initial distribution half-life ~10 min; terminal elimination half-life ~1-3 hours (biphasic); prolongs in renal impairment.
Terminal half-life 12-15 hours in healthy adults; prolonged to 24-36 hours in hepatic impairment.
Primarily hepatic metabolism (deaminated by cytidine deaminase to inactive uracil arabinoside); renal excretion of unchanged drug accounts for <10% of dose; <1% biliary/fecal.
Renal: 30-40% unchanged; biliary/fecal: 40-50% as metabolites; total clearance 0.5 L/h/kg.
Category C
Category C
Antineoplastic Antimetabolite
Antineoplastic Antimetabolite